Semaglutide produces measurable weight loss results at every stage, but the timeline is not linear — appetite drops fast, scale movement follows, and the plateau phase catches most people off guard. This guide walks through what actually happens, month by month, from your first injection through month six and beyond.

TL;DR: Semaglutide for weight loss results follow a predictable arc: appetite suppression in week 1–2, 2–4% body weight lost by month 2, and 10–15% total loss by month 6 in clinical data. The drug works best as part of a supervised program — Good Life Health's medical weight loss program pairs semaglutide with ongoing provider support to keep results on track.

Key Takeaways
  • Semaglutide results follow a predictable arc, not a straight line — appetite drops first, scale movement follows.
  • Appetite suppression typically appears within days 3–7 of the first injection.
  • The dose titrates from 0.25 mg up to a 2.4 mg maintenance ceiling over a 16-week schedule.
  • A pseudo-plateau around month three is metabolic adaptation, not drug failure.
  • STEP 1 documented a mean 14.9% body weight loss at 68 weeks.
  • Most people quit in the first three months; staying on a supervised protocol is the variable that matters.

Why This Timeline Matters

Most people quit GLP-1 therapy in the first three months — either because side effects feel permanent or because the scale stalls unexpectedly around month two. Knowing what is physiologically normal at each stage is the difference between staying the course and stopping early. The STEP 1 trial (2021, n=1,961) documented a mean weight loss of 14.9% of body weight at 68 weeks — but that number is an average across a slow ramp, not a straight line.

What You'll Need

  • A licensed prescriber and valid prescription for semaglutide (brand names Wegovy or compounded versions through a medically supervised program)
  • Injection supplies: alcohol swabs, auto-injector pen or syringes
  • A food diary or tracking app — calorie intake data helps your provider calibrate dosing
  • Baseline labs: fasting glucose, HbA1c, lipid panel, thyroid (TSH)
  • 15–30 minutes per week for provider check-ins
  • A realistic expectation: 68 weeks, not 8

The Steps — Month by Month

Month 1 (Weeks 1–4): Dose 0.25 mg — The Calibration Phase

The starting dose is 0.25 mg once weekly. This is not a therapeutic weight loss dose — it is a titration step to let your GI tract adjust. Most people notice reduced appetite within days 3–7: meals feel filling at smaller portions, and food "noise" (constant thoughts about eating) quiets noticeably.

What you'll lose: Aggregated data from STEP 1 shows roughly 1–2% of body weight in month one. On a 220 lb person that is 2–4 lbs. Do not chase a bigger number this early.

Most common mistake: Cutting calories too aggressively in week one. GI side effects — nausea, mild cramping — are nearly universal at 0.25 mg. Eating too little amplifies them. Aim for 80–90% of your normal intake and let the drug do the work.

Expected outcome: Reduced hunger ratings by self-report, 1–3 lbs down, GI side effects present but manageable.

Month 2 (Weeks 5–8): Dose 0.5 mg — The Appetite Shift

At week five your prescriber moves you to 0.5 mg. This is where subjective appetite suppression becomes objective calorie reduction. Most people eat 300–500 fewer calories per day without deliberate restriction — a documented mechanism from the STEP trials.

What you'll lose: Cumulative loss by end of month two typically reaches 4–6% of starting body weight in clinical settings. That is 8–13 lbs on a 220 lb baseline.

Why this matters for 2026: Compounded semaglutide availability has tightened since the FDA removed semaglutide from the shortage list in late 2024, making prescriber-supervised programs that source Wegovy directly more reliable than gray-market options.

Most common mistake: Skipping protein. Semaglutide suppresses total appetite, not just carbohydrate cravings. Without deliberate protein intake (0.7–1g per lb of target body weight), muscle loss accounts for a disproportionate share of what you are dropping on the scale.

Expected outcome: Consistent weekly loss of 0.5–1 lb per week, clothes fitting differently, energy stable or slightly improved.

Month 3 (Weeks 9–12): Dose 1.0 mg — The First Plateau Test

The 1.0 mg dose is the midpoint of the standard titration schedule. This is also where the first pseudo-plateau appears — weight loss slows for 2–3 weeks not because the drug stopped working but because your body has adjusted metabolic rate to match your new intake level.

What you'll lose: By the end of week 12, STEP trial participants averaged approximately 6% body weight loss. The distribution is wide — some are at 4%, some at 9%.

What to do: This is the correct time for a check-in with your provider to review labs and assess whether a dose adjustment makes sense. Do not self-adjust.

Most common mistake: Blaming the drug and stopping. The plateau at month three is almost always metabolic adaptation, not drug failure. A diet break, a protein refeed, or a move to 1.7 mg resolves it in most cases.

Clinical note

The plateau at month three is almost always metabolic adaptation, not drug failure. Labs tell a different story than the scale — fasting glucose and triglycerides typically show measurable improvement by week 12, even before significant weight loss.

Expected outcome: Slower weekly loss (0.25–0.5 lb/week), which is normal. Labs improve — fasting glucose and triglycerides typically show measurable improvement by week 12 even before significant weight loss.

Month 4 (Weeks 13–16): Dose 1.7 mg — The Acceleration Window

For many patients, the step from 1.0 mg to 1.7 mg produces the most dramatic single-month results of the entire protocol. Appetite suppression deepens, and for some patients, early satiety becomes a management challenge — meaning you need to schedule meals rather than rely on hunger cues.

What you'll lose: Cumulative loss by end of month four averages 8–10% of starting body weight in the STEP 1 data.

Concrete check: If you started at 220 lbs, month four puts most supervised patients at 198–202 lbs — crossing the psychologically significant 10% threshold.

Most common mistake: Letting meal skipping become chronic. Skipping meals at 1.7 mg frequently causes fatigue, hair thinning (telogen effluvium, often appearing 3–4 months after acute caloric deficit), and muscle loss.

Expected outcome: 0.75–1.5 lbs per week, high patient satisfaction scores, notable improvement in blood pressure and fasting insulin.

Month 5 (Weeks 17–20): Dose 2.4 mg — Maximum Dose, Sustained Loss

Wegovy's maximum approved dose is 2.4 mg. Not all patients need it — if you are losing consistently at 1.7 mg, there is no clinical reason to escalate. The 2.4 mg dose is reserved for patients whose loss has stalled and whose GI tolerance allows it.

What you'll lose: By week 20, aggregate STEP data shows 10–12% total body weight loss for the average participant.

Side effect reality in 2026: Nausea and constipation remain the most-reported adverse events at 2.4 mg, affecting approximately 44% and 24% of users respectively per the STEP 1 publication. Both are dose-dependent and manageable.

Most common mistake: Treating 2.4 mg as a finish line. Maximum dose is a maintenance tool, not an endpoint. Your food relationship, activity habits, and hormonal environment all determine whether you keep the weight off when you eventually taper.

Expected outcome: Loss rate stabilizes at 0.5–0.75 lbs per week, which is sustainable and metabolically safer than faster rates.

Month 6 and Beyond: The 14.9% Destination

The STEP 1 trial's 14.9% mean weight loss occurred at 68 weeks.

STEP 1 trial outcomes (2021, n=1,961)
14.9%
mean body weight loss at 68 weeks
86.4%
of participants achieved at least 5% weight loss
69.1%
of participants achieved at least 10% weight loss

Six months in — roughly week 24 — most supervised patients are at 10–14%. The final 1–5 percentage points accumulate slowly over months seven through sixteen.

Why providers matter here: Dose maintenance, lab monitoring (thyroid, kidney function, lipids), and behavioral support all drive whether patients hit the upper end of results (20%+) or stay at the lower end (8–10%). Good Life Health's medical weight loss program includes ongoing labs and provider visits rather than one-time prescriptions.

Troubleshooting

Persistent nausea past week four: Usually signals too-fast eating or meals that are too large. Reduce portion size by 25% and eat slower. If nausea is daily and severe, contact your provider — dose back-titration (returning to 0.5 mg) is standard protocol.

Scale has not moved in three weeks: Normal at months one and three. Abnormal at months four and five. At months four–five, request a provider review of your calorie intake and consider adding 20–30 minutes of resistance training three days per week.

Hair thinning starting at months three–four: Almost always telogen effluvium from caloric deficit, not from semaglutide itself. Increase protein to 1g per lb of target body weight and add biotin. This resolves within four to six months in most cases.

Injection site reactions: Redness, itching, or nodules at the injection site affect roughly 5% of users. Rotate sites — abdomen, thigh, upper arm — on a weekly cycle. Room-temperature injections cause fewer reactions than cold-pen injections.

Fatigue at higher doses: Often a sodium/electrolyte issue from reduced food volume. Add a daily electrolyte supplement (300–500 mg sodium, 200 mg magnesium). Check with your provider before adding potassium.

GI slowdown / constipation: GLP-1 receptors slow gastric motility. Increase water to 80–100 oz per day, add 25–35g dietary fiber, and discuss a magnesium citrate supplement with your provider if the problem persists past two weeks.

Tools and Resources

  • Prescriber program: Good Life Health medical weight loss — supervised semaglutide prescriptions, labs, and ongoing check-ins
  • Membership details: goodlifehealth.ai/membership — pricing, visit cadence, what is included
  • Hormone panel: If fatigue or stalled results persist past month three, a thyroid and hormone workup may explain the gap. Hormone optimization from Good Life Health covers the relevant labs.
  • Food tracking apps: Cronometer or MyFitnessPal for protein and calorie visibility
  • STEP 1 clinical data (Wilding et al., NEJM 2021): Primary reference for the weight loss percentages cited throughout this guide

What to Do Next

If you are pre-start, the highest-value step is a supervised evaluation — not a self-prescribed starting dose. See how to start medical weight loss with a doctor for a detailed walkthrough of the intake process, what labs to request, and what red flags disqualify you from GLP-1 therapy.

FAQ

What are typical semaglutide for weight loss results by month six? Clinical trial data from STEP 1 (2021) shows an average of 10–14% body weight loss at 24 weeks on supervised semaglutide. Individual results range from 6% to 20%+ depending on starting weight, dose adherence, and diet quality.

How fast does semaglutide start working for weight loss? Appetite suppression typically appears within days 3–7 of the first injection. Measurable scale movement — 2–4 lbs — usually shows up by the end of week four. The drug reaches full therapeutic effect at 2.4 mg, which requires a 16-week titration schedule.

Is semaglutide better than tirzepatide for weight loss in 2026? Tirzepatide (Zepbound/Mounjaro) produces slightly higher average weight loss — 20–22% vs 15% for semaglutide — based on head-to-head data from the SURMOUNT-5 trial published in 2025. Semaglutide remains the better-tolerated option for patients with significant GI sensitivity at baseline.

What happens if you stop taking semaglutide? Weight regain is documented and substantial. The STEP 4 withdrawal study (2022) showed participants regained two-thirds of lost weight within one year of stopping. A structured taper, not abrupt cessation, is the standard clinical protocol.

Does semaglutide require a prescription? Yes. Semaglutide — as Wegovy or in compounded form — requires a prescription from a licensed prescriber. As of 2026, telehealth programs with in-house medical staff can prescribe it without an in-person visit in most U.S. states.

How much weight can you lose on semaglutide in 2026? The published mean from STEP 1 is 14.9% of body weight over 68 weeks. A 220 lb person losing 14.9% ends at 187 lbs — about 33 lbs. Real-world outcomes tracked in 2026 observational studies cluster around 10–12% at one year, reflecting lower adherence rates outside clinical settings.

What dose of semaglutide is used for weight loss? The FDA-approved weight loss formulation (Wegovy) starts at 0.25 mg/week and titrates to a maximum of 2.4 mg/week over 16–20 weeks. The 2.4 mg dose is the maintenance dose. Note: Ozempic's maximum approved dose is 2.0 mg and is not FDA-approved for weight loss specifically.

Can semaglutide help with hormonal weight gain? Semaglutide reduces overall adiposity, which improves insulin sensitivity and can secondarily improve sex hormone balance — particularly in women with PCOS. It does not directly replace thyroid hormone or treat cortisol dysfunction. A full hormone panel before starting is the correct sequence, not an either/or choice.

One Last Thing

The 14.9% figure from STEP 1 is the headline number, but the more instructive stat is this: in that same trial, 86.4% of semaglutide participants achieved at least 5% weight loss by week 68, and 69.1% achieved at least 10%. Those numbers tell you the drug works for a large majority of people who stick with it — the variable is adherence to a supervised protocol over the full timeline, not the drug's ceiling.

Related Guides

References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
  2. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). 2021. pubmed.ncbi.nlm.nih.gov/33755728/